Why the study?
Does 5-iminodaunorubicin reduce mitochondrial membrane damage compared to adriamycin?
Population
Mitochondrial model (specifics not stated in abstract)
Comparison
5-iminodaunorubicin vs Adriamycin
Design
Preclinical
Authors
Loading...
Structural modification of anthracyclines merits exploration to limit mitochondrial cardiotoxicity; leaves open human translation.
Does 5-iminodaunorubicin reduce mitochondrial membrane damage compared to adriamycin?
Modifying the anthraquinone moiety of anthracyclines may be a promising strategy to reduce cardiotoxic mitochondrial damage.
Pollakis et al. (1983) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: